Rgenix Stock

rgenix.comBioTechFounded: 2010Funding to Date: $83.5MM

Rgenix is a developer of first-in-class drugs that target key pathways in cancer progression.

Register for Details

For more details on financing and valuation for Rgenix, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Masoud Tavazoie Ph.D
Co-Founder, Board Member and Chief Executive Officer
Sohail Tavazoie Ph.D
Co-Founder, Scientific & Clinical Advisor
Robert Wasserman MD
Chief Medical Officer
Roger Waltzman MD
Chief Medical Officer
Eric Rowinsky MD
Board Member & President
David Darst
Chief Operating Officer & Board Observer

Board Members

Antoine Papiernik
Sofinnova Partners
David Darst
Eric Rowinsky MD
Masoud Tavazoie Ph.D
Nancy Chang Ph.D
Nilesh Kumar Ph.D
Novo Holdings
Noam Ohana
Conegliano Ventures
Peter Van Vlasselaer Ph.D
Saeed Tavazoie Ph.D

Other companies like Rgenix in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$197.73MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

Rgenix, Inc. announced today that industry veteran Robert Wasserman, MD, has joined the Rgenix management team as its new Chief Medical Officer.
Rgenix announces $40 million in a Series C financing in support of further development of the company’s clinical and pre-clinical oncology programs.